The concept that IDH1R132H heterozygosity is anti-oncogenic and incompatible with tumor growth seems at odds with the fact that greater than 70% of WHO grade II and grade III gliomas and secondary glioblastomas harbor IDH1 mutations [1–3]. This evidence concerns the gene IDH1 and glioma.